Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab

OBJECTIVE: To assess onset of effect in three placebo- or nonsteroidal anti-inflammatory drug (NSAID)-controlled trials of tanezumab in patients with moderate-to-severe osteoarthritis. METHODS: Post-hoc nonparametric Kaplan–Meier analyses were used to estimate median time to first improvement and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, D.J., Schnitzer, T.J., Hall, J., Semel, D., Davignon, I., Cappelleri, J.C., Bushmakin, A.G., Abraham, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
ORIGINAL PAPER
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718254/
https://www.ncbi.nlm.nih.gov/pubmed/36474952
http://dx.doi.org/10.1016/j.ocarto.2022.100294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718254/
https://www.ncbi.nlm.nih.gov/pubmed/36474952
http://dx.doi.org/10.1016/j.ocarto.2022.100294

Ejemplares similares